ReviewRegenerative therapy2026
Leukocyte-rich versus leukocyte-poor platelet-rich plasma for Osteoarthritis: A systematic review.
Review in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Outcome Analysis of Leukocyte-Rich Platelet-Rich Plasma, Leukocyte-Poor Platelet-Rich Plasma, and Injectable Platelet-Rich Fibrin in the Management of Chronic Plantar Fasciitis: A Prospective Comparative Study.Journal of orthopaedic case reports · 2026Article
- Leukocyte-Rich Platelet-Rich Plasma Improves Cartilage Repair After High Tibial Osteotomy: A Second-Look Arthroscopic Study.Biomedicines · 2026Article
- Human BMP4 mRNA Encapsulated in Lipid Nanoparticle for Bone and Articular Cartilage Repair in Aged Mice.Journal of functional biomaterials · 2026Article
- Case Report: Nebulized autologous platelet-rich plasma associated with quantitative CT and clinical changes in a patient with COPD and chronic hypersensitivity pneumonitis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoarthritis is an increasingly prevalent condition with limited conservative treatments. Platelet-rich plasma (PRP) therapy has gained attention, but its efficacy may depend on the type used. In particular, leukocyte-rich (LR-PRP) and leukocyte-poor (LP-PRP) formulations may influence outcomes, yet direct comparisons are limited. Methodology: a systematic literature search and analysis of clinical trials, through PubMed database, were conducted to evaluate the effect of leukocyte - rich and leukocyte - poor platelet rich plasma in the treatment of osteoarthritis. Results: 11 articles were analyzed individually, including both in vivo and Conclusion: This review highlights that current evidence is insufficient to determine whether adding leukocytes to PRP provides a clinical benefit in the treatment of osteoarthritis. Overall, results generally show no significant differences between LR-PRP and LP-PRP, suggesting that both may be effective. Although leukocytes were initially thought to induce inflammation, there is no conclusive evidence that local reactions are directly caused by them. Given the limitations of existing studies, further research is required to clarify the role of leukocytes in PRP therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.